02.14.13
Charles River Laboratories
4Q Revenues: $280.1 million(-4%)
4Q Earnings: $18.5 million(-32%)
FY Revenues: $1.1 billion (-1%)
FY Earnings: $97.9 million(-11%)
Comments: Research Models and Services (RMS) segment sales were down 6% to $171.8 million in the quarter, driven by lower sales of research models, offset by Endotoxin sales and Microbial Detection (EMD) business, which included the acquisition of Accugenix. Preclinical Services (PCS) segment sales were flat at $108.3 million. For the year RMS sales were $695.1 million, down 2% and PCS sales were $434.4 million, down 1%.
4Q Revenues: $280.1 million(-4%)
4Q Earnings: $18.5 million(-32%)
FY Revenues: $1.1 billion (-1%)
FY Earnings: $97.9 million(-11%)
Comments: Research Models and Services (RMS) segment sales were down 6% to $171.8 million in the quarter, driven by lower sales of research models, offset by Endotoxin sales and Microbial Detection (EMD) business, which included the acquisition of Accugenix. Preclinical Services (PCS) segment sales were flat at $108.3 million. For the year RMS sales were $695.1 million, down 2% and PCS sales were $434.4 million, down 1%.
